Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;20(8):797-810.
doi: 10.4103/1735-1995.168405.

Resveratrol and liver: A systematic review

Forouzan Faghihzadeh  1 , Azita Hekmatdoost  1 , Payman Adibi  2
Affiliations
Review

Resveratrol and liver: A systematic review

Forouzan Faghihzadeh et al. J Res Med Sci. 2015 Aug.

Abstract

Background: Recent studies demonstrated that resveratrol has many therapeutic effects on liver disorders. Resveratrol significantly increased survival after liver transplantation, decreased fat deposition, necrosis, and apoptosis which induced by ischemia in Wistar rats. It provided liver protection against chemical, cholestatic, and alcohol injury. Resveratrol can improve glucose metabolism and lipid profile and decrease liver fibrosis and steatosis. Furthermore, it was able to alter hepatic cell fatty acid composition. According to extension of liver disease around the world and necessity of finding new threat, this review critically examines the current preclinical in vitro and in vivo studies on the preventive and therapeutic effects of resveratrol in liver disorders.

Materials and methods: A search in PubMed, Google Scholar, and Scopus was undertaken to identify relevant literature using search terms, including "liver," "hepatic," and "Resveratrol." Both in vivo and in vitro studies were included. No time limiting considered for this search.

Results: A total of 76 articles were eligible for this review. In these articles, resveratrol shows antioxidative properties in different models of hepatitis resulting in reducing of hepatic fibrosis.

Conclusion: Resveratrol could reduce hepatic steatosis through modulating the insulin resistance and lipid profile in animals. These high quality preclinical studies propose the potential therapeutic implication of resveratrol in liver disorders especially those with hepatic steatosis. Resveratrol can play a pivotal role in prevention and treatment of liver disorders by reducing hepatic fibrosis.

Keywords: Antioxidant; fibrosis; liver; liver disorders; liver dysfunction; liver transplantation; nonalcoholic fatty liver; resveratrol; steatosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design
See this image and copyright information in PMC

References

    1. Brown L, Kroon PA, Das DK, Das S, Tosaki A, Chan V, et al. The biological responses to resveratrol and other polyphenols from alcoholic beverages. Alcohol Clin Exp Res. 2009;33:1513–23. - PMC - PubMed
    1. Luther DJ, Ohanyan V, Shamhart PE, Hodnichak CM, Sisakian H, Booth TD, et al. Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs. 2011;29:380–91. - PubMed
    1. Wang G, Guo X, Chen H, Lin T, Xu Y, Chen Q, et al. A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Bioorg Med Chem Lett. 2012;22:2114–8. - PubMed
    1. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506. - PubMed
    1. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. Front Biosci. 2007;12:4839–54. - PubMed